Understanding CARdiac Events in Breast Cancer
In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused o
| Condition(s) | Breast Cancer, Cardiotoxicity, Cardiomyopathies, Chemotherapeutic Toxicity, Heart Failure, Oncology |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | In Ireland, over 3,000 patients are diagnosed with breast cancer annually, and 1 in 9 Irish women will be diagnosed with breast cancer in their lifetime. There is evidence that female breast cancer survivors are more likely to die of cardiovascular disease than their age-matched counterparts. This research is focused on evaluating pathways for identifying, managing, and overcoming side effects of cancer therapies that can negatively impact quality-of-life and overall outcomes for women during and after cancer treatment. The Cardio-oncology research team at GUH plan to capitalize on their expertise in both cancer care and cardiology to develop a care pathway for cancer patients who are at increased risk of developing heart disease. |
| Who can participate | Inclusion Criteria: * Women aged ≥ 18 years * Ability to read and understand English * Breast Cancer Stage I- III planned to receive systemic chemotherapy Exclusion Criteria: * Patients not for systemic chemotherapy with curative intent * Patients who are unable to co-operate with the study protocol * Patients who are unable to give informed consent |
| Ages | 18 Years to 90 Years |
| Sex | Female |
| Lead sponsor | National University of Ireland, Galway, Ireland |
| Locations | Galway, Ireland; Galway, Ireland; Mayo, Ireland; Sligo, Ireland |
| Start date | 2023-01-14 |
| NCT ID | NCT05921279 |
| Official listing | https://clinicaltrials.gov/study/NCT05921279 |